ANTX - AN2 Therapeutics, Inc.

4.74
-0.060   -1.266%

Share volume: 258,840
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$4.80
-0.06
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
9.22%
1 Month
36.99%
3 Months
319.47%
6 Months
264.62%
1 Year
288.52%
2 Year
100.00%
Key data
Stock price
$4.74
P/E Ratio 
N/A
DAY RANGE
$4.61 - $5.03
EPS 
-$1.20
52 WEEK RANGE
$1.00 - $6.91
52 WEEK CHANGE
$282.26
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
35.941 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$259,744
AVERAGE 30 VOLUME 
$350,183
Company detail
CEO: Eric Easom
Region: US
Website: an2therapeutics.com
Employees: 20
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Recent news